ClinicalTrials.Veeva
Menu

Find clinical trials for Endometrial Cancer in Chicago, IL

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Cancer
Ovarian Cancer
Breast Cancer
Carcinoma
Triple Negative Breast Cancer
Non-Small-Cell Lung Carcinoma
Ovarian Epithelial Carcinoma

Endometrial Cancer trials near Chicago, IL, USA:

Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer

is evaluating a drug called Avelumab alone and in combination with Talazoparib or Axitinib as a possible treatment for recurrent or metastatic endometrial...

Active, not recruiting
Metastatic Endometrial Cancer
Drug: Avelumab
Drug: Axitinib

Phase 2

Dana-Farber Cancer Institute
Dana-Farber Cancer Institute

Chicago, Illinois, United States and 3 other locations

This is a Phase IB/II multi-cohort study designed to evaluate the efficacy and safety of targeted agents with or without cancer immune check ...

Enrolling
Endometrial Cancer
Drug: Talazoparib
Drug: Atezolizumab - 21 Day Cycle

Phase 1, Phase 2

Alliance Foundation Trials

Chicago, Illinois, United States and 20 other locations

letrozole in advanced stage, persistent or recurrent endometrioid endometrial cancer at 6 months. Treatment will continue until eit...

Active, not recruiting
Endometrial Cancer
Drug: Letrozole
Drug: Abemaciclib

Phase 2

Gynecologic Oncology Group (GOG)

Chicago, Illinois, United States and 28 other locations

(paclitaxel + carboplatin) followed by maintenance durvalumab with or without olaparib for patients with newly diagnosed advanced or recurrent endometrial...

Active, not recruiting
Endometrial Neoplasms
Drug: Carboplatin
Biological: durvalumab

Phase 3

AstraZeneca
AstraZeneca

Chicago, Illinois, United States and 202 other locations

for maintenance selinexor in participants with advanced or recurrent endometrial cancer. Participants with primary stage IV or recu...

Active, not recruiting
Endometrial Cancer
Drug: Matching placebo for selinexor
Drug: Selinexor

Phase 3

Karyopharm Therapeutics
Karyopharm Therapeutics

Oak Lawn, Illinois, United States and 77 other locations

Locations recently updated

DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when com...

Enrolling
Endometrial Cancer
Drug: Carboplatin
Drug: Paclitaxel

Phase 3

AstraZeneca
AstraZeneca

Evanston, Illinois, United States and 242 other locations

Researchers are looking for new ways to treat people with endometrial cancer (EC) who have previously received treatment with plati...

Enrolling
Endometrial Cancer
Drug: Paclitaxel
Drug: Nab-paclitaxel

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Evanston, Illinois, United States and 243 other locations

This study evaluates navtemadlin as maintenance treatment for patients with advanced or recurrent endometrial cancer (EC) who have ...

Enrolling
Endometrial Cancer
Drug: Navtemadlin
Drug: Navtemadlin Placebo

Phase 2, Phase 3

Kartos Therapeutics
Kartos Therapeutics

Hinsdale, Illinois, United States and 82 other locations

The goal of this clinical study is to find out how the study drug, sacituzumab govitecan (SG) works in participants with endometrial cancer...

Enrolling
Endometrial Cancer
Drug: Paclitaxel
Drug: Sacituzumab govitecan-hziy

Phase 3

Gilead Sciences
Gilead Sciences

Chicago, Illinois, United States and 186 other locations

to evaluate the efficacy and safety of ACR-368 as monotherapy or with ultra-low dose gemcitabine (ULDG) sensitization in participants with endometrial...

Enrolling
Endometrial Adenocarcinoma
Drug: ACR-368
Drug: Gemcitabine

Phase 2

Acrivon Therapeutics

Chicago, Illinois, United States and 68 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems